MetaCap

Lite Strategy (LITS) vs Telomir Pharmaceuticals (TELO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lite Strategy (LITS) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 52.8% versus a loss of 71.6%. Telomir Pharmaceuticals is the larger company by market cap ($26.8 million vs $24.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LITS-52.79%TELO-71.56%
+21%-28%-76%
Nov 21, 20251 yearNov 20, 2026
LITS-83.21%TELO-92.72%
+92%-5%-101%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LITS versus TELO key metrics
MetricLITSTELO
Share price$0.8026$0.364
Market cap$23.99M$26.82M
1-day change-4.03%-17.24%
YTD return-39.20%-72.63%
1-year return-52.79%-71.56%
5-year return-98.46%—
EPS (TTM)$-1.38$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-71.15M$-10.41M
52-week high$1.99$1.58
52-week low$0.69$0.353
Distance from 52-week high-59.67%-76.96%
Analyst consensus—none
Avg. price target upside—+998.90%
Average volume524.33K126.14K
Shares outstanding29.88M73.68M
Employees5—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LITS has outperformed TELO by 18.8 percentage points over the past year.

About Lite Strategy

LITS stock →

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Telomir Pharmaceuticals

TELO stock →

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.

Health Care · Biotechnology: Pharmaceutical Preparations

LITS vs TELO FAQ

Which is bigger, Lite Strategy or Telomir Pharmaceuticals?

Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $26.82M compared with $23.99M for Lite Strategy (LITS).

Which stock has performed better over the past year, LITS or TELO?

LITS returned -52.79% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.

Are Lite Strategy and Telomir Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons